UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X]QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017.

[ ]QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended
June 30, 2023

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______.

Commission FileNumber 000-26108

 

AMERICAN CANNABIS COMPANY, INC.

(Exact name of registrant as specified in its charter)

Delaware90-1116625
Delaware
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)90-1116625
(I.R.S. Employer
Identification No.)

5690 Logan St. Unit A
Denver, 200 Union Street, Ste. 200

Lakewood, Colorado
80228
(Address of principal executive offices)

80216
(Zip Code)

(303) 974-4770

(Registrant’s telephone number, including area code)

(303) 974-4770
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of "large“large accelerated filer," "accelerated filer"” “accelerated filer,” “smaller reporting company,” and "smaller reporting company"“emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]Accelerated filer [ ] ☐
Non-accelerated filer [ ]
 (Do not check if a
smaller reporting company)
Smaller reporting company [X]
Emerging growth company [ ]

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes [ ]    ☐   No [X] ☒

On November 20, 2017, 51,434,050

At June 30, 2023, and August 14, 2023, 92,152,938 shares of common stock were outstanding.   
outstanding, respectively. 

 
 


  
TABLE OF CONTENTS

Page
PART I. FINANCIAL INFORMATIONPage
Item 1.FINANCIAL STATEMENTS (Unaudited):STATEMENTS:3
CONDENSED CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBERJUNE 30, 20172022 (UNAUDITED) AND DECEMBER 31, 2016.20213
CONDENSED CONSOLIDATED STATEMENTSTATEMENTS OF OPERATIONS FOR THE THREE AND NINE SIX MONTHS ENDED JUNE 30, 2022 AND 2022 (UNAUDITED).4
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY FOR THE THREE AND SIX MONTHS ENDED SEPTEMBERJUNE 30, 20172022 AND 2016.2021 (UNAUDITED)45
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWFLOWS FOR THE NINESIX MONTHS ENDED JUNE 30, 2022 AND 2021 (UNAUDITED).6
SEPTEMBER 30, 2017 AND 2016.5
NOTES TO THE UNAUDITED CONDENSEND CONSOLIDATED FINANCIAL STATEMENTS.67
Item 2.MANAGEMENT'S DISCCUSSIONMANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS1229
Item 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK1634
Item 4.CONTROLS AND PROCEDURES1634
PART II. OTHER INFORMATION
Item 1.LEGAL PROCEEDINGS1736
Item 1A.RISK FACTORS1736
Item 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS1736
Item 3.DEFAULTS UPON SENIOR SECURITIES1736
Item 5.4.OTHER INFORMATION  MINE SAFETY DISCLOSURES1737
Item 6.5.EXHIBITSOTHER INFORMATION1837
SIGNATURESItem 6.19EXHIBITS38
SIGNATURES39

 
 

PART I—FINANCIAL INFORMATION

ITEM 1.FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS

AMERICAN CANNABIS COMPANY, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited) (UNAUDITED)

 June 30, December 31,
 September 30, 2017 December 31, 2016 2023 2022
ASSETS                
Current Assets                
Cash and equivalents $1,877,249  $751,038 
Accounts receivable, net  404,894   164,451 
        
Cash and Equivalents $92,742  $117,547 
Accounts Receivable, Net  293,304   469,111 
Deposits  9,595   9,595 
Inventory  30,640   42,500   508,289   352,971 
Prepaid expenses and other current assets  14,135   9,825 
Prepaid Expenses and Other Current Assets  77,952   73,933 
Total Current Assets  2,326,919   967,814   981,882   1,023,157 
                
Property and equipment - net  12,625   11,639 
Property and Equipment - Net  437,990   427,669 
        
Other Assets  4,500   4,500         
        
Intangible Assets, net amortization  1,130,575   1,223,242 
Goodwill  1,332,113   1,332,113 
Right of Use Assets - Operating Leases, net  562,948   604,020 
Long Term Deposits  6,000   6,000 
Total Other Assets  3,031,637   3,165,375 
TOTAL ASSETS  2,344,044   983,953  $4,451,509  $4,616,201 
                
LIABILITIES AND SHAREHOLDERS’ EQUITY                
Current Liabilities                
Accounts payable  11,142   55,782 
Accounts payable, related party   —     14,325 
Advances from clients  57,800   222,188 
Accrued and other current liabilities  23,702   36,724 
        
Accounts Payable $809,328  $679,163 
Advances from Clients  156,213   280,705 
Accrued and Other Current Liabilities  440,031   233,348 
Stock payable  17,021   74,343 
Right of Use Liabilities, current  183,386   181,661 
Litigation Settlement, current  12,500   100,000 
Note payables, current  550,000   550,000 
Total Current Liabilities  92,644   329,019   2,168,478   2,099,220 
                
Total Liabilities  92,644   329,019 
        
Commitments and contingencies        
LONG TERM LIABILITIES        
Litigation Settlement  75,000   75,000 
Right of Use Liabilities – LT  379,562   422,359 
LTD Note Payable  335,660   150,000 
Total Long-Term Liabilities  790,222   647,359 
TOTAL LIABILITIES  2,958,701   2,746,579 
                
Shareholders’ Equity                
Preferred stock, $0.01 par value; 5,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively  —     —   
Common stock, $0.00001 par value; 100,000,000 shares authorized; 51,434,050 and 49,847,593 issued and outstanding at September 30, 2017 and December 31, 2016, respectively  514   498 
Preferred Stock, $0.01 par value, 5,000,000 shares authorized; 0 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively          
Common stock, $0.00001 par value; 500,000,000 shares authorized; 85,727,938 and 92,152,938 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively  922   922 
Additional paid-in capital  6,486,870   5,389,384   12,023,751   11,949,409 
Accumulated deficit  (4,235,984)  (4,734,948)  (10,531,864)  (10,080,709)
Total Shareholders’ Equity  2,251,400   654,934   1,492,809   1,869,622 
                
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $2,344,044  $983,953  $4,451,509  $4,616,201 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.statements.

3
 

AMERICAN CANNABIS COMPANY, INC.

RESULTSCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)(UNAUDITED)

               
  Three Months Ended Six Months Ended
  June 30, June 30, June 30, June 30,
  2023 2022 2023 2022
Revenues        
Consulting Services $307,685   146,976  $468,500  $242,048 
Product & Equipment  374,209   4,360,689   737,758   4,673,834 
Cannabis Products  170,835   236,620   358,856   448,249 
Total Revenues  852,730   4,744,285   1,565,115   5,364,131 
                 
Cost of Revenues                
Cost of Consulting Services  58,085   31,515   103,085   47,922 
Cost of Products and Equipment  290,079   3,717,977   507,646   3,964,197 
Cost of Cannabis Products  138,179   354,157   311,488   543,828 
Total Cost of Revenues  486,343   4,103,649   922,219   4,555,947 
Gross Profit  366,386   640,636   642,895   808,184 
                 
Operating Expenses                
General and Administrative  437,996   741,418   1,081,600   1,333,738 
Selling and Marketing  52,849   48,425   117,384   101,527 
Stock Based Compensation Expense  7,935   34,274   17,021   65,309 
Total Operating Expenses  498,779   824,117   1,216,005   1,500,574 
Loss from Operations  (132,393)  (183,481)  (573,109)  (692,390)
                 
Other Income (Expense)                
Interest (expense)  (32,728)  (18,233)  (64,363)  (45,357)
Debt Forgiveness                    
Other income  176,966   30,911   186,316   44,769 
Total Other (Expense) Income  144,237   (12,678)  (121,953)  (588)
Net Loss  11,844   (170,803)  (451,156)  (692,978)
Income Tax Expense                    
NET LOSS $11,844  $(170,803) $(451,156) $(692,978)
Basic net loss per common share $(0) $(0) $(0.01) $(0.01)
Basic and diluted weighted average common shares outstanding  85,727,938   85,244,422   84,795,246   84,336,545 

  For the three months ended September 30, For the nine months ended September 30,
  2017 2016 2017 2016
Revenues        
     Consulting Services $916,676  $143,610  $2,331,735  $603,083 
     Product and equipment  73,637   93,290   228,516   617,869 
Total Revenues  990,313   236,900   2,560,251   1,220,952 
                 
Cost of Revenues                
     Cost of consulting services  124,677   38,120   273,753   137,920 
     Cost of products and equipment  38,824   66,614   170,029   447,470 
Total Cost of Revenues  163,501   104,734   443,782   585,390 
                 
Gross Profit  826,812   132,166   2,116,469   635,562 
                 
Operating expenses                
     General and administrative  362,966   353,292   1,442,992   884,733 
     Investor relations  10,381   11,129   27,371   29,197 
     Selling and marketing  72,115   22,855   149,419   63,332 
     Research and development  63,685   520   7,048   1,932 
Total Operating expenses  451,830   387,796   1,626,830   979,194 
                 
Gain (Loss) from Operations  374,982   (255,630)  489,639   (343,632)
                 
Other Income (Expense)                
     Loss on debt extinguishment  —     (59,128)  —     (59,128)
     Change in derivative liabilities  —     66,449   —     66,449 
     Interest (expense)  156   19,605   9,325   (29,935)
Total Other Income (expense)  156   (14,314)  9,325   (24,644)

 

Net Income (Loss) before taxes

  375,138   (269,944)  498,964   (368,276)
NET INCOME (LOSS) $375,138  $(269,944) $498,964  $(368,276)
                 
Basic gain (loss) per common share* $0.01  $(0.00)* $0.01  $(0.00)
Diluted loss per share of common stock $0.01  $(0.00)  0.01   (0.00)
                 
Basic weighted average common shares outstanding  51,434,050   46,375,168   51,434,050   45,628,580 
Diluted weighted average common shares outstanding  51,468,214   46,375,168   51,462,284   45,628,580 
* denotes a loss of less than $(0.01).                

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.statements.

4
 4

AMERICAN CANNABIS COMPANY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSCHANGES IN SHAREHOLDERS’ EQUITY

(Unaudited)

(UNAUDITED) 

  Nine Months Nine Months
  Ended September 30, 2017 Ended September 30, 2016
     
Cash flows from operating activities:        
Net income (loss) $498,964  $(382,276)
Adjustments to reconcile net income (loss) to net cash        
provided by (used in) operating activities:        
Bad debt expense  73,280   66,431 
Depreciation  4,013   3,744 
Amortization of discount on convertible note payable  —     26,302 
Stock-based compensation to employees  401,809   16,240 
Common stock issued for settlement expense  110,000   —   
Stock-based compensation to service providers  —     9,198 
Change in derivative liabilities  —     (64,419)
Consulting Services in Exchange for Joint Venture  —     —   
Changes in operating assets and liabilities:        
Accounts receivable  (313,723)  (203,900)
Deposits  —     2,845 
Inventory  11,860   (238)
Prepaid expenses and other current assets  (4,310)  (16,150)
Advances from Clients  (164,388)  (57,326)
Accrued liabilities and other current liabilities  (44,347)  (91,484)
Accounts payable  (44,640)  (117,206)
Net cash used in operating activities  528,518   (619,983)
Cash flows from investing activities:        
Purchases of property and equipment  (5,000)  (3,290)
Net cash used in investing activities  (5,000)  —   
Cash flows from financing activities:        
Proceeds from issuance of convertible notes payable  —     139,065 
Proceeds from issuance of common stock  602,693   —   
Net cash provided by financing activities  602,693   139,065 
Net increase (decrease) in cash and cash equivalents  1,126,211   (484,208)
Cash and cash equivalents at beginning of period  751,038   555,780 
Cash and cash equivalents at end of period $1,877,249  $71,572 
Supplemental disclosure of cash flow information:        
Cash paid for interest $—    $—   
Cash paid for income taxes $—    $—   
Non-Cash investing and financing activities:        
Conversion of note payable to common shares $—    $71,500 
Common stock returned and cancelled  1   —   
Common stock issued for debt converted in prior year  2     

FOR THE THREE MONTHS ENDED JUNE 30, 2023 AND 2022

                
  Common Stock Additional
Paid-In
 Subscription Accumulated Total
Shareholders’
  Shares Amount Capital Receivable Deficit Equity
Balance, March 31, 2022  84,727,938  $847  $11,729,486  $(25,165) $(9,969,692) $1,735,476 
Subscription Receivable Paid  —               25,165        25,165 
Stock based compensation third party  1,000,000   10   64,990             65,000 
Net Loss  —                    (170,803)  (170,803)
Balance, June 30, 2022  85,727,938  $857  $11,794,476  $    $(10,140,495) $1,654,838 

  Common Stock Additional
Paid-In
 Subscription Accumulated Total
Shareholders’
  Shares Amount Capital Receivable Deficit Equity
Balance, March 31, 2023  95,132,938  $922  $12,023,751  $0  $(10,543,709) $1,480,694 
Subscription Receivable Issued  0   0   0             0 
Stock based compensation issued to employees  0   0   0             0 
Stock issued for cash  0   0   0             0 
Net Loss  —                    11,844   11,844 
Balance, June 30, 2023  92,152,938  $922  $12,023,751  $    $(10,531,865) $1,492,808 

FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022

  Common Stock Additional
Paid-In
 Subscription Accumulated Total
Shareholders’
  Shares Amount Capital Receivable Deficit Equity
Balance, December 31, 2021  81,902,938  $819  $11,565,679  $    $(9,447,517) $2,118,981 
Stock based compensation to employees  325,000   3   46,204             46,207 
Subscription Receivable Paid  —               (25,651)       (25,651)
Stock based compensation to third party  1,000,000   10   64,990             65,000 
Stock issued for cash  2,500,000   25   117,603   25,651        142,793 
Net Loss  —                    (692,978)  (692,978)
Balance, June 30, 2022  85,727,938  $857  $11,794,476  $    $(10,140,495) $1,654,838 

  Common Stock Additional
Paid-In
 Subscription Accumulated Total
Shareholders’
  Shares Amount Capital Receivable Deficit Equity
Balance, December 31, 2022  92,152,938  $922  $11,949,409  $    $(10,080,709) $1,869,622 
Stock based compensation to employees  —          74,342             74,342 
Stock-based compensation to service provider  —                            
Stock issued for cash  —                            
Net Loss  —                    (451,159)  (451,156)
Balance, June 30, 2023  92,152,938  $922  $12,023,751  $    $(10,531,865) $1,492,808 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.statements.

5
 5

AMERICAN CANNABIS COMPANY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

        
  For the Six Months Ended
  June 30, June 30,
  2023 2022
CASH FLOWS FROM OPERATING ACTIVITIES        
Net Loss $(451,155) $(692,978)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization  121,449   72,520 
Stock-based compensation to employees       65,306 
Stock-based compensation to third party       13,542 
Debt Forgiveness          
Changes in operating assets and liabilities:        
Accounts receivable  175,807   (194,122)
Inventory  (155,318)  (1,616)
Prepaid expenses and other current assets  (4,021)  (3,444)
Right to Use Lease Asset  41,072   (161,008)
Long Term Deposits       (32,347)
Accounts Payable  130,165   266,991 
Advances from Clients  (124,492)  1,277,874 
Accrued and other current liabilities  223,703   6,231 
Litigation Settlement Liability  (87,500)  (131,250)
Operating Lease Liability  (41,072)  161,008 
Net Cash Provied by (Used In) Operating Activities $(171,362) $646,707 
         
CASH FLOWS FROM INVESTING ACTIVITIES:        
Purchase of property and equipment  (39,101)  (1,122)
Acquisition of Assets          
Intangible assets       (9,876)
Net Cash Used in Investing Activities $(39,101) $(10,998)
         
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from sale of common stock       117,629 
Proceeds from note payable          
Payment of note payable       (550,000)
LTD Note Payable  185,660      
Net Cash (Used) Provided by Financing Activities $(185,660) $(432,371)
         
NET INCREASE IN CASH  (24,804)  203,338 
         
CASH AT BEGINNING OF PERIOD  117,547   670,423 
         
CASH AT END OF PERIOD $92,742  $873,761 
         
SUPPLEMENTAL CASH FLOW INFORMATION:        
Cash paid for income taxes $    $   
Cash paid for interest $    $   
Stock Based Compensation Third Party $    $65,000 
         
Stock Issued for Receivables $    $   
Stock Issued for Acquisition $    $   

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATEDUNAUDITED FINANCIAL STATEMENTS

FOR THE THREESIX AND NINETHREE MONTHS ENDED SEPTEMBERJUNE 30, 2017 and 2016
(Unaudited)2023 AND 2022

Note 1. DescriptionPrinciples of Consolidation.

The unaudited condensed consolidated financial statements for the Business

six and three months ended June 30, 2023, and 2022 include the accounts of American Cannabis Company, Inc. and its wholly owned subsidiary, Hollister & Blacksmith, Inc., doing business as American Cannabis Company, Inc. Intercompany accounts and transactions have been eliminated.

Note 2. Description of Business.

American Cannabis Company, Inc. and its wholly-owned subsidiary Company, Hollister & Blacksmith, Inc., doing business as American Cannabis Consulting (“American Cannabis Consulting”), (collectively “the “Company”) are based in Denver, Colorado. The Company operatesColorado, and operate a fully-integrated business model that features end-to-end solutions for businesses operating in the regulated cannabis industry in states and countries where cannabis is regulated and/or has been de-criminalized for medical use and/or legalized for recreational use. The Company providesWe provide advisory and consulting services specific to this industry, designsdesign industry-specific products and facilities, and manages a strategic group partnership that offerssell both exclusive and non-exclusive customer products commonly used in the industry. American

On March 11, 2021, the Company entered into a material definitive agreement to acquire the assets of Medihemp, LLC, and its wholly owned subsidiary SLAM Enterprises, LLC, and Medical Cannabis Caregivers, Inc., each an entity organized and operating under the laws of the State of Colorado, and all doing business as “Naturaleaf” in the medicinal cannabis industry in Colorado. The material definitive agreement closed on April 29, 2021.

Naturaleaf sold and assigned to the Company Inc. isthe following assets:

1.Three Medical Marijuana (MMC) Store Licenses;

2.One Marijuana Infused Product Licenses (MIPS); and,

3.One Option Premises Cultivation License (OPC); and,

4.Related real property assets, goodwill, and related business assets.

The aggregate consideration paid for the assets was $2,890,000, which consisted of (i) a publicly listed company quotedcash payment of $1,100,000, (ii) the issuance of a promissory note to the owner of Naturaleaf in the principal amount of $1,100,000 (the “Seller Note”), and (iii) the issuance of 3,000,000 shares of the Company’s restricted common stock valued at $0.23 per share or $690,000. See Note 4.

On April 29, 2022, the Company and Naturaleaf amended the promissory note to restructure the payment schedule ("First Amendment"). The parties agreed that in consideration of the Company's payment of $550,000, and outstanding interest of $110,000, a new promissory note with a maturity date of April 29, 2023, in the principal amount of $550,000 and 12% interest accruing annually, would resolve all Company payments of the purchase price. The parties entered into the First Amendment, and the Company paid the consideration of $550,000 in principal and $110,000 in interest.

On June 8, 2023, the Company and Naturaleaf amended the promissory note ("Second Amendment") to restructure the remaining payments due to be made by the Company under the amended Note, totaling principal and interest of $651,162.50 ("Second Amendment"). Pursuant to the Second Amendment, the Company agreed to pay $150,000 by June 30, 2023; $100,000 by July 31, 2023; and the balance by May 1, 2024. The Company made both payments and granted Naturaleaf a first-priority lien and security interest on the OTCQB underassets of the symbol “AMMJ”.Registrant, securing the payment and performance of the payment schedule.

On May 31, 2023, the Company sold Colorado State License No. 402-01065 (Medical Marijuana Store); City of Colorado Springs License No. 0850714L in exchange for $100,000. The closing of the transaction is pending approval by the Colorado Marijuana Enforcement Division. As of May 31, 2023, the Company discontinued its operations at the Palmer Park Boulevard, Ste. A, Colorado Springs, CO location. The Company will continue to rent the facility on a month-to-month tenancy pending final regulatory approval from the Colorado Marijuana Enforcement Division concerning the change of ownership.

Note 2. 3. Summary of Significant Accounting Policies

Basis of Accounting

The accompanying unaudited condensed consolidated financial statements areof the Company have been prepared in accordance with accounting principles generally accepted in the United States of America, ("pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include normal recurring adjustments that are necessary for a fair presentation of the results for the periods presented.

7

Unaudited Interim Financial Statements

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP"GAAP for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the unaudited consolidated financial statements do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for (a) the financial position, (b) the result of operations, and (c) cash flows have been made in order to make the financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year.

Going Concern

Accounting Standards Codification (“ASC”). Topic 205-40, Presentation of Financial Statements - Going Concern ("ASC 205-40") requires management to assess the Company’s ability to continue as a going concern for one year after the date the financial statements are issued. Under ASC 205-40, management has the responsibility to evaluate whether conditions and/or events raise substantial doubt about our ability to meet future financial obligations as they become due within one year after the date that the financial statements are issued. As required by this standard, management’s evaluation shall initially not take into consideration the potential mitigating effects of management’s plans that have not been fully implemented as of the date the financial statements are issued.

Our assessment included the preparation of a detailed cash forecast that included all projected cash inflows and outflows. During 2022, we secured additional cash financings through the sales and issuances of our common stock through. However, we continue to focus on growing our revenues. Accordingly, operating expenditures may exceed the revenue we expect to receive for the foreseeable future. We also have a history of operating losses, negative operating cash flows, and negative working capital, and expect these trends to continue into the foreseeable future.

As of the date of this Quarterly Report on Form 10-Q, while we believe we have adequate capital resources to complete our near-term operations, there is no guarantee that such capital resources will be sufficient until such time we reach profitability. We may access capital markets to fund strategic acquisitions or ongoing operations on terms we believe are favorable. The timing and amount of capital that may be raised are dependent on market conditions and the terms and conditions upon which investors would require to provide such capital. We may utilize debt or sell newly issued equity securities through public or private transactions.

8

There can be no assurance that we will be able to obtain additional funding on satisfactory terms or at all. In addition, no assurance can be given that any such financing, if obtained, will be adequate to meet our capital needs and support our growth. If additional funding cannot be obtained on a timely basis and on satisfactory terms, our operations would be materially negatively impacted; however, we have been successful in accessing capital markets in the past, and we are confident in our ability to access capital markets again if needed.

The Company has electedan accumulated deficit and recurring losses and expects continuing future losses. These factors raise substantial doubt about the Company’s ability to continue as a fiscalgoing concern. The Company’s primary source of operating funds during the six months ended June 30, 2023, and the year ending onended December 31. Certain balance sheet reclassifications31, 2022, has been from funds generated from proceeds from the sale of common stock and operations. The Company has experienced net losses from operations since its inception but expects these conditions to improve in 2023 and beyond as it develops its business model. The Company has an accumulated deficit at June 30, 2023, and requires additional financing to fund future operations.

The Company’s existence is dependent upon management’s ability to develop profitable operations and obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

The accompanying unaudited consolidated financial statements have been made to prior period balances to reflectprepared on a going-concern basis, which contemplates the current period’s presentation format; such reclassifications had no impact onrealization of assets and the Company’s consolidated statementssatisfaction of operations or consolidated statementsliabilities in the normal course of cash flows and had no material impact on the Company’s consolidated balance sheets.business. 

9

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE SIX AND THREE MONTHS ENDED JUNE 30, 2023 AND 2022

Use of Estimates in Financial Reporting

The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the condensed consolidated financial statements during the periods presented. Actual results could differ from these estimates. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period in which they are deemed to be necessary. Significant estimates made in the accompanying consolidated financial statements include but are not limited to following:following those related to revenue recognition, allowance for doubtful accounts and unbilled services, lives and recoverability of equipment and other long-lived assets, the allocation of the asset purchase price, contingencies, and litigation. The Company is subject to uncertainties, such as the impact of future events, economic, environmental, and political factors, and changes in the business climate;climate; therefore, actual results may differ from those estimates. When no estimate in a given range is deemed to be better than any other when estimating contingent liabilities, the low end of the range is accrued. Accordingly, the accounting estimates used in the preparation of the Company'sCompany’s consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as the Company'sCompany’s operating environment changes. Changes in estimates are made when circumstances warrant. Such changes and refinements in estimation methodologies are reflected in reported results of operations;operations; if material, the effects of changes in estimates are disclosed in the notes to the unaudited consolidated financial statements.

Unaudited Interim Financial Statements

10

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE SIX AND THREE MONTHS ENDED JUNE 30, 2023 AND 2022

Cash and Cash Equivalents

The accompanying unauditedCompany considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents are held in operating accounts at a major financial statementsinstitution. Cash balances may exceed federally insured limits. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date. As of June 30, 2023, and December 31, 2022, the Company had cash balances in excess of FDIC-insured limits of $250,000.

Accounts Receivable

Accounts receivables are recorded at the net value of face amount less an allowance for doubtful accounts. The Company evaluates its accounts receivable periodically based on specific identification of any accounts receivable for which the Company deems the net realizable value to be less than the gross amount of accounts receivable recorded; in these cases, an allowance for doubtful accounts is established for those balances. In determining its need for an allowance for doubtful accounts, the Company considers historical experience, analysis of past due amounts, client creditworthiness, and any other relevant available information. However, the Company’s actual experience may vary from its estimates. If the financial condition of its clients were to deteriorate, resulting in their inability or unwillingness to pay the Company’s fees, it may need to record additional allowances or write-offs in future periods. This risk is mitigated to the extent that the Company receives retainers from its clients prior to performing significant services.

The allowance for doubtful accounts, if any, is recorded as a reduction in revenue to the extent the provision relates to fee adjustments and other discretionary pricing adjustments. To the extent the provision relates to a client’s inability to make required payments on accounts receivables, the provision is recorded in operating expenses. As of June 30, 2023, and December 31, 2022, the Company’s allowance for doubtful accounts was $4,071 and $4,071, respectively. The Company recorded a bad debt expense of $12,000 in the three months ending June 30, 2023. No bad debt expense was recorded for the similar period in 2022.

Deposits

Deposits comprise advance payments made to third parties for rent, utilities, and inventory for which the Company has not yet taken title. When the Company takes title to inventory for which deposits are made, the related amount is classified as inventory, then recognized as a cost of revenues upon sale.

Inventory

Inventory comprises products and equipment the Company owns to be sold to end customers. The Company’s inventory as it relates to its soil products and equipment is valued at cost using the first-in, first-out, and specific identification methods, unless and until the market value for the inventory is lower than cost, in which case an allowance is established to reduce the valuation to net realizable value. As of June 30, 2023, and December 31, 2022, market values of all the Company’s inventory were greater than cost, and accordingly, no such valuation allowance was recognized.

Inventory also consists of pre-harvested cannabis plants and related end products. Inventory is valued at the lower of cost or net realizable value. Costs of inventory purchased from third-party vendors for retail sales at dispensaries are determined using the first in, first out method. Costs are capitalized to cultivated inventory until substantially ready for sale. Costs include direct and indirect labor, consumables, materials, packaging supplies, utilities, facilities costs, quality and testing costs, production-related depreciation, and other overhead costs. The Company periodically reviews physical inventory for excess, obsolete, and potentially impaired items. The reserve estimate for excess and obsolete inventory is based on expected future use and on an assessment of market conditions. At June 30, 2023, the Company’s management determined that a reserve for excess and obsolete inventory was not necessary

11

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE SIX AND THREE MONTHS ENDED JUNE 30, 2023 AND 2022

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets are primarily comprised of advance payments made to third parties for independent contractors’ services or other general expenses. Prepaid services and general expenses are amortized over the applicable periods, which approximate the life of the contract or service period.

Significant Clients and Customers

During the six months ended June 30, 2023, three customers accounted for 42.5% of the Company’s total revenues for the period.

During the six months ended June 30, 2022, three customers accounted for 42.5% of the Company’s total revenues.

Property and Equipment, net

Property and Equipment are stated at net book value, cost less depreciation. Maintenance and repairs are expensed as incurred. Depreciation of owned equipment is provided using the straight-line method over the estimated useful lives of the assets, ranging from two to seven years. Costs associated with in-progress construction are capitalized as incurred, and depreciation is consummated once the underlying asset is placed into service. Property and equipment are reviewed for impairment as discussed below under “Accounting for the Impairment of Long-Lived Assets.” The Company did not capitalize any interest as of June 30, 2023, and December 31, 2022.

Goodwill

Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed. The Company accounts for goodwill under ASC Topic 350, Intangibles-Goodwill and Other. The Company tests goodwill for impairment annually or more frequently whenever events or circumstances indicate impairment may exist. Goodwill is stated at cost less accumulated impairment losses. The Company completes its goodwill impairment test annually in the fourth quarter. The Company recognized goodwill of $1,332,113 during the year ended December 31, 2022, as part of the Naturaleaf Acquisition.

The Company does not have been preparedany other indefinite-lived intangible assets. 

In accordance with FASB ASC 350, “Intangibles – Goodwill and Other,” the impairment test for goodwill uses a two-step approach. Step one compares the estimated fair value of a reporting unit with goodwill to its carrying value. If the carrying value exceeds the estimated fair value, step two must be performed. Step two compares the carrying value of the reporting unit to the fair value of all of the assets and liabilities of the reporting unit (including any unrecognized intangibles) as if the reporting unit was acquired in a business combination. If the carrying amount of a reporting unit’s goodwill exceeds the implied fair value of its goodwill, an impairment loss is recognized in an amount equal to the excess.

12

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE SIX AND THREE MONTHS ENDED JUNE 30, 2023 AND 2022

Intangible Assets, net

Definite life intangible assets at June 30, 2023, include licenses and brand names recognized as part of the Naturaleaf Acquisition. Intangible assets are recorded at cost. Licenses and brand names represent the estimated fair value of these items at the date of acquisition, April 30, 2021. Intangible assets are amortized on a straight-line basis over their estimated useful life. Licenses are assigned a life of 15 years, and tradenames are assigned a life of 5 years. During the six months ended June 30, 2023, the Company recognized a depreciation and amortization expense of $121,449.

Accounting for the Impairment of Long-Lived Assets

The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Upon such an occurrence, the recoverability of assets to be held and used is measured by comparing the carrying amount of an asset to forecasted undiscounted net cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. For long-lived assets held for sale, assets are written down to fair value, less cost to sell. Fair value is determined based on discounted cash flows, appraised values, or management’s estimates, depending upon the nature of the assets. The Company had not recorded any impairment charges related to long-lived assets as of June 30, 2023, and December 31, 2022.

Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities.

Our financial instruments include cash, deposits, accounts receivable, accounts payables, advances from clients, accrued expense, and other current liabilities. The carrying values of these financial instruments approximate their fair value due to their short maturities.  

Revenue Recognition

We have adopted the following accounting principles related to revenue recognition: (a) FASB ASU 2016-12 “Revenue from Contracts with Customers (Topic 606).

13

Our service and product revenues arise from contracts with customers. Service revenue includes Operations Divisions' consulting revenue. Product revenue includes (a) Operations Division product sales (So-Hum Living Soils), (b) Equipment sales division, and (c) Cannabis sales division. The majority of our revenue is derived from distinct performance obligations, such as time spent delivering a service or the delivery of a specific product.

We may also enter contracts with customers that identify a single or few distinct performance obligations but that also have non-distinct, underlying performance obligations. These contracts are typically fulfilled within one to six months. Only an insignificant portion of our revenue would be assessed for allocation between distinct (contractual) performance obligations and non-distinct deliverables between reporting periods, and accordingly, we do not record a contract asset for completed, non-distinct performance obligations prior to invoicing the customer.

We recognize revenue in accordance with U.S. GAAPASC 606 using the following five steps to identify revenues:

(1)Identify the contract with the Customer. Our customary practice is to obtain written evidence, typically in the form of a contract or purchase order.

(2)Identify the performance obligations in the contract. We have rights to payment when services are completed in accordance with the underlying contract, or for the sale of goods when custody is transferred to our customers either upon delivery to our customers’ locations, with no right of return or further obligations.

(3)Determination of the transaction price. Prices are typically fixed, and no price protections or variables are offered.

(4)Allocation of the transaction price to the performance obligations in the contract. Transaction prices are typically allocated to the performance obligations outlined in the contract.

(5)Recognize Revenue when (or as) the entity satisfies a performance obligation. We typically require a retainer for all or a portion of the goods or services to be delivered. We recognize revenue as the performance obligations detailed in the contract are met.

Advances from Client deposits are contract liabilities with customers that represent our obligation to either transfer goods or services in the future or refund the amount received. Where possible, we obtain retainers to lessen our risk of non-payment by our customers. Advances from Clients' deposits are recognized as revenue as we meet specified performance obligations as detailed in the contract.

Product and Equipment Sales

Revenue from product and equipment sales, including delivery fees, is recognized when an order has been obtained from the customer, the price is fixed and determinable when the order is placed, the product is delivered, the title has been transferred, and collectability is reasonably assured. Generally, our suppliers drop-ship orders to our clients with destination terms. The Company realizes revenue upon delivery to the customer. Given the facts that (1) our customers exercise discretion in determining the timing of when they place their product order; and, (2) the price negotiated in our product sales contracts is fixed and determinable at the time the customer places the order, we are not of the opinion that our product sales indicate or involve any significant financing that would materially change the amount of revenue recognized under the contract, or would otherwise contain a significant financing component for interim financial informationus or the customer under FASB ASC Topic 606. During the six months that ended June 30, 2023, and 2022, sales returns were $0.

14

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE SIX AND THREE MONTHS ENDED JUNE 30, 2023 AND 2022

Consulting Services

We also generate revenues from professional services consulting agreements. These arrangements are generally entered into: (1) on an hourly basis for a fixed fee; or (2) on a contingent fee basis. Generally, we require a complete or partial prepayment or retainer prior to performing services. For hourly-based fixed-fee service contracts, we utilize and rely upon the proportional performance method, which recognizes revenue as services are completed. Under this method, to determine the amount of revenue to be recognized, we calculate the amount of completed work in comparison to the total services to be provided under the arrangement or deliverable. We segregate upon entry into a contract any advances or retainers received from clients for fixed fee hourly services into a separate “Advances from Clients account and only recognize revenues as we incur and charge billable hours, and then deposit the funds earned into our operating account. Because our hourly fees for services are fixed and determinable and are only earned and recognized as revenue upon actual performance, we are of the opinion that such arrangements are not an indicator of a vendor or customer-based significant financing that would materially change the amount of revenue we recognize under the contract or would otherwise contain a significant financing component under FASB ASC Topic 606.

Occasionally, our fixed-fee hourly engagements are recognized under the completed performance method. Some fixed fee arrangements are for the completion of a final deliverable or act which is significant to the arrangement. These engagements do not generally exceed a one-year term. If the performance is for a final deliverable or act, we recognize revenue under the completed performance method, in which revenue is recognized once the final act or deliverable is performed or delivered for a fixed fee. Revenue recognition is affected by several factors that change the estimated amount of work required to complete the deliverable, such as changes in scope, timing, awaiting notification of license award from local government, and the level of client involvement. Losses, if any, on fixed-fee engagements are recognized in the period in which the loss first becomes probable and reasonably estimable. FASB ASC Topic 606 provides a practical expedient to disregard the effects of a financing component if the period between payment and performance is one year or less. As our fixed fee hourly engagements do not exceed one year, no significant customer-based financing is implicated under FASB ASC Topic 606. During the six months ended June 30, 2023, and 2022, we incurred no losses from fixed fee engagements that terminate prior to completion. We believe that if an engagement terminates prior to completion, we can recover the costs incurred related to the services provided.

We primarily enter arrangements for which fixed and determinable revenues are contingent and agreed upon, achieving a pre-determined deliverable or future outcome. Any contingent revenue for these arrangements is not recognized until the contingency is resolved and collectability is reasonably assured.

Our arrangements with clients may include terms to deliver multiple services or deliverables. These contracts specifically identify the services to be provided with the instructions to Form 10-Qcorresponding deliverable. The value for each deliverable is determined based on the prices charged when each element is sold separately or by other vendor-specific objective evidence (“VSOE”) or estimates of stand-alone selling prices. Revenues are recognized in accordance with our accounting policies for the elements as described above (see Product Sales). The elements qualify for separation when the deliverables have value on a stand-alone basis, and Regulation S-X.  Accordingly, the financial statementsvalue of the separate elements can be established by VSOE or an estimated selling price.

While assigning values and identifying separate elements requires judgment, selling prices of the separate elements are generally readily identifiable as fixed and determinable as we also sell those elements individually outside of a multiple services engagement. Contracts with multiple elements typically incorporate a fixed-fee or hourly pricing structure. Arrangements are typically terminable by either party upon sufficient notice or do not include allprovisions for refunds relating to services provided.

Reimbursable expenses, including those relating to travel, other out-of-pocket expenses, and any third-party costs, are included as a component of revenues. Typically, an equivalent amount of reimbursable expenses is included in total direct client service costs. Reimbursable expenses related to time and materials and fixed-fee engagements are recognized as revenue in the informationperiod in which the expense is incurred and footnotes required by generally accepted accounting principles for complete financial statements. Incollectability is reasonably assured. Taxes collected from customers and remitted to governmental authorities are recognized as liabilities and paid to the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year.appropriate government entities.

15
 6

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE SIX AND THREE MONTHS ENDED JUNE 30, 2023 AND 2022

Cannabis Sales

Revenues consist of the retail sale of cannabis and related products. Revenue is recognized at the point of sale for retail customers. Payment is typically due upon transferring the goods to the customer or within a specified time permitted under the Company’s credit policy. Sales discounts were not material during the six months ended June 30, 2023.

Loyalty Reward Program

The Company offers a loyalty reward program to its dispensary customers that provides a discount on purchases based on the total purchase amount at the time of purchase. Management has determined that there is no separate performance obligation to the reward program, i.e., the accumulation and redemption of points, and as such, the Company recognizes the revenue at the time of purchase.

Costs of Revenues

The Company’s policy is to recognize costs of revenue in the same manner in conjunction with revenue recognition. Cost of revenue includes the costs directly attributable to revenue recognition and includes compensation and fees for services, travel, and other expenses for services and costs of products and equipment. Selling, general and administrative expenses are charged to expense as incurred.

Advertising and Promotion Costs

Advertising and Promotion costs are included as a component of selling and marketing expense and are expensed as incurred. During the six months ended June 30, 2023, and 2022, these expenses were $117,384 and $101,527, respectively.

Shipping and Handling Costs

For product and equipment sales, shipping and handling costs are included as a component of cost of revenues.

Stock-Based Compensation

Restricted shares are awarded to employees and entitle the grantee to receive shares of common stock at the end of the established vesting period. The grant's fair value of the grant is based on the stock price on the date of grant. The Company recognizesgrant date. We recognize related compensation costs on a straight-line basis over the requisite vesting period of the award.award, which has been one year from the grant date. During the threesix months ended SeptemberJune 30, 2017, the Company had no employee stock-based compensation expense. During the nine months ended September 30, 2017, the Company had employee2023, and 2022, stock-based compensation expense for restricted shares for Company employees was $17,021 and $65,309, respectively.

Research and Development

As a component of $401,809. Compensation expenseour equipment and supplies offerings, from time to time, we design and develop our own proprietary products to meet demand in markets where current offerings are insufficient. These products include but are not limited to The Satchel™, Cultivation Cube™, So-Hum Living Soils™, and the HDCS™. Costs associated with the development of new products are expensed as incurred as research and development operating expenses. During the six months ending June 30, 2023, and 2022, our research and development costs were de minimis.

16

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE SIX AND THREE MONTHS ENDED JUNE 30, 2023 AND 2022

Income Taxes

The Company’s corporate status changed from an S Corporation, which it had been since its inception, to a C Corporation during the year ended December 31, 2014. As provided in Section 1361 of the Internal Revenue Code, for warrantsincome tax purposes, S Corporations are not subject to corporate income taxes; instead, the owners are taxed on their proportionate share of the S Corporation’s taxable income. We recognize deferred tax assets and optionsliabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns in accordance with applicable accounting guidance for accounting for income taxes, using currently enacted tax rates in effect for the year in which the differences are expected to reverse. We record a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. For the year ended December 31, 2022, due to cumulative losses since our corporate status changed, we recorded a valuation allowance against our deferred tax asset that reduced our income tax benefit for the period to zero. As of June 30, 2023, and December 31, 2022, we had no liabilities related to federal or state income taxes, and the carrying value of our deferred tax asset was zero.

Due to its cannabis operations, the Company is basedsubject to the limitations of Internal Revenue Code (“IRC”) Section 280E, under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E.

Net Loss Per Common Share

The Company reports net loss per common share in accordance with FASB ASC 260, “Earnings per Share”. This statement requires a dual presentation of basic and diluted earnings with a reconciliation of the numerator and denominator of the earnings per share computations. Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share is equal to basic earnings per share because there are no potential dilatable instruments that would have an anti-dilutive effect on earnings. Diluted net loss per share gives effect to any dilutive potential common stock outstanding during the period. The computation does not assume conversion, exercise, or contingent exercise of securities since that would have an anti-dilutive effect on earnings.

Related Party Transactions

The Company follows FASB ASC subtopic 850-10, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

17

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE SIX AND THREE MONTHS ENDED JUNE 30, 2023 AND 2022

Impact of COVID-19 Pandemic

On March 11, 2020the World Health Organization declared the current coronavirus (“COVID-19”) outbreak to be a global pandemic. In response to this declaration and the rapid spread of COVID-19 within the United States, federal, state and local governments throughout the country have imposed varying degrees of restrictions on social and commercial activity to promote social distancing in an effort to slow the spread of the illness. These measures had a significant adverse impact on many sectors of the economy, including retail commerce.

In response to state and local measures and for the protection of both employees, the Company made required changes to operations, which did not have a material impact on operations or the financial condition of the Company.

While the state and local governments have eased restrictions on restrictions and activities, it is possible that a resurgence in COVID-19 cases could prompt a return to or new tighter restrictions to be instituted in the future. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of these unaudited condensed consolidated financial statements.

Recent Accounting Pronouncements

The Company does not believe that any recently issued effective pronouncements, or pronouncements issued but not yet effective if adopted, would have a material effect on the accompanying unaudited condensed consolidated financial statements.

18

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE SIX AND THREE MONTHS ENDED JUNE 30, 2023 AND 2022

Note 4. Naturaleaf Asset Acquisition

On April 30, 2021, the Company closed its acquisition of the assets of Medihemp, LLC, and its wholly owned subsidiary SLAM Enterprises, LLC, and Medical Cannabis Caregivers, Inc., each an entity organized and operating under the laws of the State of Colorado, and all doing business as “Naturaleaf” in the medicinal cannabis industry in Colorado.

Naturaleaf agreed to sell or assign to the Company the following assets:

1.Three Medical Marijuana (MMC) Store Licenses;

2.One Marijuana Infused Product Licenses (MIPS); and,

3.One Option Premises Cultivation License (OPC); and,

4.Related real property assets, goodwill, and related business assets.

The aggregate consideration paid for the Assets was $2,890,000, which consisted of (i) a cash payment of $1,100,000, (ii) the issuance of a promissory note to the owner of Naturaleaf in the principal amount of $1,100,000 (the “Seller Note”), and (iii) the issuance of 3,000,000 shares of the Company’s restricted common stock valued at $0.23 per share or $690,000.

On April 29, 2022, the Company and Naturaleaf amended the promissory note to restructure the payment schedule ("First Amendment"). The parties agreed that in consideration of the Company's payment of $550,000, and outstanding interest of $110,000, a new promissory note with a maturity date of April 29, 2023, in the principal amount of $550,000 and 12% interest accruing annually, would resolve all Company payments of the purchase price. The parties entered into the First Amendment, and the Company paid the consideration of $550,000 in principal and $110,000 in interest.

On June 8, 2023, the Company and Naturaleaf amended the promissory note ("Second Amendment") to restructure the remaining payments due to be made by the Company under the amended Note, totaling principal and interest of $651,162.50 ("Second Amendment"). Pursuant to the Second Amendment, the Company agreed to pay $150,000 by June 30, 2023; $100,000 by July 31, 2023; and the balance by May 1, 2024. The Company made both payments and granted Naturaleaf a first-priority lien and security interest on the assets of the Registrant, securing the payment and performance of the payment schedule.

The asset acquisition was accounted for under the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations. As the acquirer for accounting purposes, the Company has estimated the fair value of Medihemp LLC and Medical Cannabis Caregivers, Inc.’s (hereafter “Naturaleaf’s”) assets acquired and conformed the instrumentsaccounting policies of Naturaleaf to its own accounting policies. The Company expenses certain legal, auditing and licensing costs with the acquisition of $83,095. 

As part of the acquisition, the owners of Naturaleaf retained the outstanding cash balance on the grant date whichof the acquisition and had agreed to the payment of all outstanding accounts payables and related party advances.

19

At December 31, 2022, the Company performed an evaluation of Naturaleaf tangible and intangible assets and goodwill as of the acquisition date. The following table summarizes the final fair value allocation of the purchase price as of April 30, 2021:

Business Combination, Segment Allocation

     
Current Assets $15,000 
Inventory  72,172 
Property, Plant and Equipment  26,715 
Other Assets  6,000 
Total Tangible Assets  119,887 
     
Tradenames and Trademarks  660,000 
Licenses  800,000 
Total Intangible Assets  1,460,000 
     
Goodwill  1,332,113 
Total Consideration $2,912,000 

Goodwill from the acquisition primarily relates to the future economic benefits arising from the assets acquired, the assembled workforce acquired and synergies between the cultivation and retail operations and is determined usingconsistent with the Black-Scholes valuation model. Company’s stated intentions and strategy. Other assets include inventory and fixed assets.

On May 31, 2023, the Company sold Colorado State License No. 402-01065 (Medical Marijuana Store); City of Colorado Springs License No. 0850714L in exchange for $100,000. The transaction's closing is pending approval by the Colorado Marijuana Enforcement Division. As of May 31, 2023, the Company discontinued its operations at the Palmer Park Boulevard, Ste. A, Colorado Springs, CO location. The Company will continue to rent the facility on a month-to-month tenancy pending final regulatory approval from the Colorado Marijuana Enforcement Division concerning the change of ownership.

During the threesix months ended SeptemberJune 30, 2017, there was no compensation expense for warrants or stock options.

Warrants

As of September 30, 2017,2023, and December 31, 2016,2022, the Company had issuedrecognized an amortization expense of $112,449 and outstanding warrants to the Company’s independent board member, to purchase up to two hundred and fifty thousand (250,000) shares of common stock at an exercise price of sixty-three cents ($0.63) per share. The warrants were fully-vested as of November 19, 2014, and expire on November 19, 2019.$72,520, respectively.

20

On August 31, 2017, the Company issued warrants to Anthony Baroud to purchase up to fifty thousand (50,000) shares of common stock at an exercise price of ninety-three cents ($0.93) per share. The warrants were fully vested as of August 31, 2017, and expire on March 1, 2018. The warrants were issued as consideration for a settlement agreement and mutual release of all claims between the Registrant and Anthony Baroud on August 31, 2017 (See Part II, Item 1).AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

OptionsFOR THE SIX AND THREE MONTHS ENDED JUNE 30, 2023 AND 2022

In addition to the warrants to the Company’s independent board member, he shall be eligible to receive options for 400,000 shares of common stock under the Company’s incentive plan, as and when duly approved by the Board of Directors. No options have been issued for the three and nine months ended September 30, 2017 and 2016.

Reclassifications

Prior year amounts have been reclassified to conform to the current year presentation.

Note 3. 5. Accounts Receivable netand Advance from Clients 

Accounts receivable net, waswere comprised of the following asfollowing:

Schedule of September 30, 2017accounts receivable and December 31, 2016:advances from clients

     
  June 30,
2023
 December 31,
2022
Accounts Receivable – Trade $293,304  $469,111 
Less:  Allowance for Doubtful Accounts  (4,071)  (4,071)
Accounts Receivable, net $289,233  $465,040 

  September 30, 2017 December 31, 2016
     
Gross accounts receivable $509,595  $195,872 
Less: allowance for doubtful accounts  (104,701)  (31,421)
Accounts receivable, net $404,894  $164,481 

The Company had bad debt expenseexpenses during the ninesix months ended SeptemberJune 30, 20172023, and 2016 of $73,2802022 were $12,000 and $13,344,$0, respectively.

21

21
 7

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE SIX AND THREE MONTHS ENDED JUNE 30, 2023 AND 2022

Our Advances from Clients had the following activity:

Schedule of advances from clients 

     
  June 30,
2023
 December 31,
2022
Beginning Balance $195,495  $111,892 
  Additional deposits received  306,409   691,769 
  Less: Deposits recognized as revenue  (346,141)  (522,663)
Ending Balance $156,213  $280,705 

Note 4.Other Assets6. Inventory

Other assets were comprisedInventory consisted of the following asfollowing:

Schedule of September 30, 2017 and December 31, 2016:inventory

  

September 30,

2017

 December 31, 2016
Deposits $4,500  $4,500 
Other assets $4,500  $4,500 

Note 5. Inventory

Inventory as of September 30, 2017 and December 31, 2016 of $30,640 and $42,500, respectively, was fully comprised of finished goods.

Note 6. Prepaid expenses and other current assets

Prepaid expenses and other current assets was comprised of the following as of September 30, 2017 and December 31, 2016:

  September 30, 2017 December 31, 2016
Prepaid expenses $14,136  $9,825 
Prepaid expenses and other current assets $14,136  $9,825 
     
  June 30,
2023
 December 31,
2022
Raw Materials - Soil $19,752  $38,464 
Work In Process - Cultivation  429,737   206,306 
Finished Goods - Soil  19,940   66,557 
Finished Goods - Cannabis Retail  38,860   41,644 
Total Inventory $508,289  $352,971 

Note 7. Property and Equipment, net

Property and equipment, asnet, was comprised of Septemberthe following:

Schedule of property, plant and equipment, net

     
  June 30,
2023
 December 31,
2022
Office equipment $47,380  $47,380 
Software  13,204   13,204 
Furniture and Fixtures  2,328   2,328 
Machinery and Equipment  517,510   364,520 
Property and equipment, gross $580,423  $427,432 
Less: Accumulated Depreciation  (142,432)  (113,650)
Property and equipment, net $437,990  $313,782 

22

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE SIX AND THREE MONTHS ENDED JUNE 30, 2017 and2023 AND 2022

Note 8. Intangibles Assets, Net

A significant amount of the Company’s current identified intangible assets were assumed upon consummation of the Naturaleaf acquisition on April 30, 2021. The Company has incurred capitalizable costs in connection with patent applications that it started work on. Identified intangible assets consisted of the following at the dates indicated below: 

Schedule of Identified intangible assets

        
  June 30, 2023
  Gross
carrying
amount
 Accumulated
amortization
 Carrying
value
 Estimated
useful
life
Licenses $800,000  ($161,219) $638,781   15 years 
Brand $660,000  ($186,669) $473,331   5 years 
Patent Applications $18,464       $18,464   —   
Total intangible assets, net $1,478,464  ($347,888) $1,130,576     

  December 31, 2022
  Gross
carrying
amount
 Accumulated
amortization
 Carrying
value
 Estimated
useful
life
Licenses $818,464  ($134,522) $683,912  15 years
Brand $660,000  ($120,670) $539,330  5 years
Total intangible assets, net $1,488,464  ($255,222) $1,233,242   

The weighted-average amortization period for intangible assets we acquired during the year ended December 31, 20162022, was approximately 11.47 years. No intangible assets were acquired during the six months ending June 30, 2023.

Amortization expense for intangible assets was $121,449 and $72,520  for the six months ended June 30, 2023 and 2022, respectively. The total estimated amortization expense for our intangible assets for the years 2022 through 2026 is summarized as follows:

Schedule of estimated amortization expense 

5 years License Brand Total
2022   25,000.00   45,000   70,000.00 
2023   33,333.33   60,000   93,333.33 
2024   33,333.33   60,000   93,333.33 
2025   33,333.33   60,000   93,333.33 
2026   33,333.33   20,000   53,333.33 
Thereafter   311,111.35       311,111.35 
    652,885.76   471,669   1,124,555.07 

 

  

September 30,

2017

 

December 31,

2016

Office equipment $9,275  $9,275 
Furniture and fixtures  9,490   10,175 
Machinery & Equipment  7,336   2,337 
Less accumulated depreciation  (13,476)  (10,148)
Property and equipment, net $12,625  $11,639 
         

23

Note 8. Related Party Transactions

During the three months ended September 30, 2017, the Company incurred $15,000 of expense payable to Prince & Tuohey CPA, Ltd., a company in which J. Michael Tuohey, the Company’s Chief Financial Officer, is an owner. Amounts owed as of September 30, 2017 and December 31, 2016, were $0 and $14,325, respectively.

8

Note 9. Accrued and Other Current Liabilities

Accrued and other current liabilities was comprisedconsisted of the following at September 30, 2017following:

Schedule of accrued and December 31, 2016:other current liabilities 

     
  June 30,
2023
 December 31,
2022
Accrued Interest $91,431  $39,130 
Accrued Payroll  32,367   22,029 
Sales Tax Payable  11,523   3,931 
Other Accrued Expenses & Payables  392,460   168,258 
Accrued and other current liabilities $440,031  $233,248 

  September 30, 2017 December 31, 2016
     
Accrued payroll liabilities  —     12,903 
Other accruals  23,702   14,986 
Accrued and other current liabilities $23,702  $36,724 
         

Note 10. Stock-based CompensationStock Payable

Restricted Shares

From time to time,The following summarizes the Company grants certain employees restricted shares of itschanges in common stock to provide further compensation in-lieupayable:

Schedule of wagesstock payable 

   
  Amount
December 31, 2022 $74,342 
    Additional Expenses Incurred    
    Payments Upon Issuance of Shares     
June 30, 2023 $74,342 

Note 11. Operating Lease Right-of-Use Asset/Operating Lease Liability

The Company leases property under operating leases. Property leases include retail and to align the employee’s interestscultivation space with the interests of its stockholders. Because vesting is based on continued employment, these equity-based incentives are also intended to attract, retainfixed rent payments and motivate personnel upon whose judgment, initiative and effort the Company’s success is largely dependent.

During the nine months ended September 30, 2017, the Company issued 430,227common shares, with a fair value of $395,809.

Warrants

As of September 30, 2017, and December 31, 2016, the Company had issued and outstanding warrants to the Company’s independent board member, to purchase uplease terms ranging from one to two hundredyears. The Company is obligated to pay the lessor for maintenance, real estate taxes, insurance, and fifty thousand (250,000) shares of common stock at an exercise price of sixty-three cents ($0.63) per share. The warrants were fully-vested as of November 19, 2014,other operating expenses on certain property leases. These expenses are variable and expire on November 19, 2019. The grant date fair valueare not included in the measurement of the warrants,lease asset or lease liability. These expenses are recognized as calculated based onvariable rent expense when incurred.

The Company’s lease portfolio consists of the Black-Scholes valuation model, was $0.59 per share.following.

As of September 30, 2017, as the exercise price per share is lower than the price per sharea result of our common shares,acquisition of Naturaleaf, we assumed the intrinsic valuefollowing leases and contingent extensions:

Schedule of outstanding warrants is $35,000. As of September 30, 2017,other operating cost and December 31, 2016, the warrants issued to the Company’s independent board member had 1.5 and 2.2 years remaining until expiration.expense

Stock Options

In addition to the warrants granted to the Company’s independent board member as described above, the Company’s independent board member shall be eligible to receive options for 400,000 shares of common stock under the Company’s incentive plan, as and when duly approved by the Board of Directors.

Stock Issuable in Compensation for Professional Services

From time to time, the Company enters into agreements whereby a professional service provider will be compensated for services rendered to the Company by shares of common stock in lieu of cash. During the nine months ended September 30, 2017, no such common stock was issued.

9o1004 S. Tejon Street, Colorado Springs, CO 80903; The Company assumed a lease originally entered into on February 12, 2016, which was the subject of an extension agreement dated April 5, 2022. The term of the lease was extended from May 1, 2022, until April 30, 2027. The Company's monthly rental payments from January 1, 2022, to May 1, 2022, were $3,700. From May 1, 2022, through the year ending December 31, 2022, monthly rent was $3,875. Remaining rental payments due for the extended period are:   May 1, 2022, to April 30, 2023, $3,875 May 1, 2023, to April 30, 2024, $4,050 May 1, 2024, to April 30, 2025, $4,225 May 1, 2025, to April 30, 2026, $4,400 May 1, 2026, to April 30, 2027, $4,575

May 1, 2022 to April 30, 2023$3,875
May 1, 2023 to April 30, 2024$4,050
May 1, 2024 to April 30, 2025$4,225
May 1, 2025 to April 30, 2026$4,400
May 1, 2026 to April 30, 2027$4,575

o2727 Palmer Park Blvd. Suite A, Colorado Springs, CO 80909 subject to a month-to month lease with a monthly rent of $5,000.

o5870 Lehman Drive Suite 200, Colorado Springs, CO 80918 The Company and landlord  previously entered into a lease in 2017 which expired December 31, 2022. At December 31, 2022, the Company's monthly rent was $2,732. On April 26, 2022, the Company and landlord entered into an extension agreement which extended the tenancy from January 1, 2023 through January 1, 2027. Rental payments due for the extended period are:   January 1, 2023 $2,898 January 1, 2024 $2,985 January 1, 2025 $3,075 January 1, 2026 $3,167 January 1, 2027 $3,262

January 1, 2023$2,898
January 1, 2024$2,985
January 1, 2025$3,075
January 1, 2026$3,167
January 1, 2027$3,262

o2611 Durango Drive, CO Springs, CO. The Company and landlord entered a lease on March 10, 2021, which terminated on May 31, 2022. On June 23, 2021, the Company and landlord entered an extension of the lease for a term of thirty-six months, beginning June 1, 2022, and terminating on June 1, 2024. On December 31, 2022, the monthly rent was $11,000. Rental payments due for the extended period are: June 1, 2022, to June 1, 2023, $11,000 June 1, 2023, to June 1, 2024, $11,880 June 1, 2025, to June 1, 2025, $12,830  

June 1, 2022 to June 1, 2023$11,000
June 1, 2023 to June 1, 2024$11,880
June 1, 2025 to June 1, 2025$12,830

Stock Issued as Consideration for Settlement Agreements.

On July 31, 2017,12, 2022, the Company entered into an accommodation for office space, effective September 1, 2022, located at 200 Union St., Suite 200, Lakewood, CO 80228. The accommodation creates no tenancy, leasehold or other real property interest concerning the Registrant. The Registrant's telephone number is unchanged. We determined under ASC 842, due to the nature of the accommodation, that the membership agreement met the criteria of ASC 842-20-25-2, and as such, it was not necessary to capitalize the accommodation, and the membership fee will be recognized on a settlement agreement, mutual release of all claims and waiver of bond for lost certificate, with Private Media Group, Inc. monthly straight-line basis.

On May 23, 2014, Private Media Group, Inc.1, 2021, as part of the Naturaleaf Acquisition, leases for grow facilities and dispensaries were assigned to the Company. These leases were determined to be operating leases under ASC 842, and such leases were capitalized. It was issued 200,000 sharesdetermined that the Tejon lease, due to the short-term nature of common stockthe lease, met the criteria of ASC 842-20-25-2 and as consideration for services rendered. Private Media Group, Inc. subsequently lostsuch it was not necessary to capitalize the stock certificate,lease, and demandedrent would be recognized on a straight-line basis.

The Company records the lease asset and lease liability at the present value of lease payments over the lease term. The leases typically do not provide an implicit rate; therefore, the Company reissueuses its estimated incremental borrowing rate at the common stock.time of lease commencement to discount the present value of lease payments. The Company’s discount rate for operating leases on June 30, 2023, was 12.5%. Leases often include rental escalation clauses, renewal options, and/or termination options that are factored into the determination of lease payments when appropriate. Lease expense is recognized on a straight-line basis over the lease term to the extent that collection is considered probable. As a result, the Company has been recognizing rents as they become payable.

As of June 30, 2023, the aggregate remaining annual lease payments of operating leases liabilities are as follows: 

Schedule of operating lease liabilities 

    
  Operating
Leases
 
2023  581,108 
Total  581,108 
Less: amount representing interest  ()
Present value of future minimum lease payments  581,108 
Less: current obligations under leases  175,611 
Long-term lease obligations $(405,497

24

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE SIX AND THREE MONTHS ENDED JUNE 30, 2023 AND 2022

Note 12. Loans Payable 

Naturaleaf Seller Note

As part of the Naturaleaf Acquisition, the Company issued a promissory note to the owner of Naturaleaf in the principal amount of $1,100,000 (the “Seller Note”). The note originally had a term of 1 year with a due date of April 30, 2022, and Private Media Group, Inc.did not require any payments prior to the due date. The note had an annual interest rate of 10%.

On April 30, 2022, the Company entered into an Amendment ("First Amendment") to the Asset Purchase Agreement to amend the Seller Note as follows; the due date of the Note was extended to April 30, 2023, and interest will accrue on the outstanding principal at a settlement agreement provided that in exchange for a complete releaserate of all claims regarding any and all compensation due to Private Media Group, Inc., Private Media Group, Inc. agreed to return 100,000 shares to treasury, and12.5%. In addition, the Company agreed to waivepay all accrued interest at April 30, 2022, and make a principal payment of bond for$500,000. On April 29, 2022, principal in the lost certificate,amount of $550,000 and to reissue Private Media Group, Inc. 100,000 common sharesaccrued interest of common stock.$110,000 was paid. At June 30, 2022, principal in the amount of $550,000 was outstanding, and interest of $9,493 had been accrued.

On August 31, 2017,June 8, 2023, the Company entered into a settlement agreement and mutual release of all claims with Anthony Baroud. The Company previously disclosed its participation in a private arbitration proceeding conductedNaturaleaf amended the promissory note to restructure the remaining payments due to be made by the American Arbitration Association, in which both claimsCompany under the amended Note, totaling principal and counterclaims were asserted byinterest of $651,162.50 ("Second Amendment"). Pursuant to the respective parties. The settlement agreement disposed of the arbitration proceeding and all claims and counterclaims between the parties with prejudice. As consideration for the dismissal and mutual release of all claims,Second Amendment, the Company agreed to pay $150,000 by June 30, 2023; $100,000 by July 31, 2023; and the balance by May 1, 2024. The Company made both payments and granted Naturaleaf a stock compensation settlement equal to $110,000 consisting of an issuance of 100,000 shares of common stock to Mr. Baroud, valued forfirst-priority lien and security interest on the purposesassets of the settlement agreement at $0.93 per share, for a total of $93,000,Registrant, securing the payment and fully vested warrants to purchase up to 50,000 shares of common stock in a cashless transaction at an exercise price determined by the closing priceperformance of the Company’s common stock on March 1, 2018. The warrants expire on March 1, 2018. If the 50,000 shares issuable to Mr. Baroud pursuant to the Cashless Warrant Agreement does not equal $17,000 for a total of $110,000, the Company agreed to issue Mr. Baroud restricted common stock, valued as of the closing price on March 1, 2018, to correct the difference so that Baroud receives the equivalent of $110,000.00.payment schedule.

Note 11. Stockholders’ Equity13. Related Party Transactions

Preferred Stock

American Cannabis Company, Inc. is authorized to issue 5,000,000 shares of preferred stock at $0.01 par value. No shares of preferred stock were issued and outstanding during the three months or nine months ended September 30, 2017, and 2016 respectively.

Common Stock

American Cannabis Company, Inc. is authorized to issue 100,000,000 common shares at $0.00001 par value per share.

The Company issued 0 shares of common stock for the three months ended September 30, 2017.

For the nine months ended September 30, 2017,On February 14, 2023, the Company issued 430,227 shares of common stock valued at $395,809 as follows:a second promissory note in exchange for $100,000 to its CEO and CFO Ellis Smith. The note is not convertible and matures on August 14, 2023. The note carries 15% interest per annum.

On January 4, 2017,November 22, 2022, the Company issued 200,000 common sharesa promissory note to Terry Buffalo.

On January 4, 2017,Ellis Smith in exchange for $150,000. Interest on the Company issued Sam D. Leucshen 50,000 common shares.

On January 4, 2017,note is 15% per annum. The note has a maturity date of May 21, 2023. If not paid within ten days of maturity, the Company issued Steven Lico 15,000 common shares.

On January 4, 2017, the Company issued Tyler A. Schlosser 20,000 common shares.

On January 4, 2017, the Company issued Robert Teran 50,000 common shares.

On January 4, 2017, the Company issued Gayle Barr 4,727 common shares.

On January 4, 2017, the Company issued Mica Renquist 7,500 common shares.

On January 4, 2017, the Company issued Gary Altman 33,000 common shares.

10

On January 4, 2017, the Company issued Randy Fleming 50,000 common shares.

On January 10, 2017, pursuant to the amended and restated Investment Agreement between the Company and Tangiers Global, LLC, the Company sold 588,841 registered common shares to Tangiers for $414,544 net of applicable financing costs received March 3, 2017.

On February 22, 2017, pursuant to the amended and restated Investment Agreement between the Company and Tangiers Global, LLC, the Company sold 320,549 registered common shares to Tangiers for $188,143 net of applicable financing costs received on March 3, 2017. 

On June 12, 2017, the Company issued Jesus Quintero 8,955 shares of restricted common stock, valued at a price of $0.67 per share, value of $6,000. The shares were issued as consideration related to a severance agreement between the Company and Mr. Quintero.

On December 28, 2016, the Company received conversion notice from a note holder to issue 237,885 shares of common stock for conversion of note principal of $25,000 and accruedcontains default interest of $2,000. The 237,885 shares18% per annum and a late charge penalty of common stock were issued in January 2017.

11

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The statements contained in this report that are not statements of historical fact, including without limitation, statements containing the words “believes,” “expects,” “anticipates” and similar words, constitute forward-looking statements that are subject to a number of risks and uncertainties. From time to time we may make other forward-looking statements. Investors are cautioned that such forward-looking statements are subject to an inherent risk that actual results may materially differ as a result of many factors, including the risks discussed from time to time in this report, including the risks described under “Risk Factors” in any filings we have made with the SEC.

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an on-going basis, we evaluate these estimates, including those related to useful lives of real estate assets, cost reimbursement income, bad debts, impairment, net lease intangibles, contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There can be no assurance that actual results will not differ from those estimates.

Background

American Cannabis Company, Inc. and subsidiary company, Hollister & Blacksmith, Inc., doing business as American Cannabis Consulting (“American Cannabis Consulting”), (collectively “the “Company”, “we”, “us”, or “our”) are based in Denver, Colorado and operate a fully-integrated business model that features end-to-end solutions for businesses operating in the regulated cannabis industry in states and countries where cannabis is regulated and/or has been de-criminalized for medical use and/or legalized for recreational use. The Company provides advisory and consulting services specific to this industry, manufactures proprietary industry solutions including; the Satchel™, SoHum Living Soils™, Cultivation Cube™ and the High Density Cultivation System.™ The Company also sells 3rd party industry-specific products and manages a strategic group partnership that offers both exclusive and non-exclusive customer products commonly used in the industry. American Cannabis Company, Inc. is a publicly listed company quoted on the OTCQB under the symbol “AMMJ”.

We were incorporated in the State of Delaware on September 24, 2001 under the name Naturewell, Inc. to develop and market clinical diagnostic products using immunology and molecular biologic technologies.

On March 13, 2013, Naturewell, Inc. completed a merger transaction whereby it acquired 100%5% of the issued and outstanding share capital of Brazil Interactive Media, Inc. (“BIMI”), which operated as a Brazilian interactive television company and television production company through its wholly owned Brazilian subsidiary company, EsoTV Brasil Promoção Publicidade Licenciamento e Comércio Ltda. (“EsoTV”). Naturewell’s Articles of Incorporation were amended to reflect a new name: Brazil Interactive Media, Inc.principal amount due.

On May 15, 2014, BIMI entered into a merger agreement (“the Merger Agreement”) to acquire 100% of the issued and outstanding American Cannabis Consulting while simultaneously disposing of 100% of the issued share capital EsoTV (“the Separation Agreement”). Both the merger with American Cannabis Consulting and disposal of EsoTV were completed on September 29, 2014. BIMI subsequently amended its Articles of Incorporation to change its name to American Cannabis Company, Inc. On October 10, 2014, American Cannabis Company, Inc changed its stock symbol from BIMI to AMMJ.

12

The foregoing descriptions of the Merger Agreement and Separation Agreement do not purport to be complete and are qualified in their entirety by the terms of such agreements, which are filed as exhibits to the Current Report on Form 8-K filed by the Company with the U.S. Securities and Exchange Commission (“SEC”) on October 3, 2014.

Immediately following the completion of the Merger Agreement, former shareholders of American Cannabis Consulting owned 31,710,628 shares of American Cannabis Company, Inc.’s common stock representing 78.4% of American Cannabis Company, Inc.’s issued and outstanding share capital. Accordingly, American Cannabis Consulting was deemed to have been the accounting acquirer in a Reverse Merger which resulted in a recapitalization of the Company. Consequently, the Company’s consolidated financial statements reflect the results of American Cannabis Consulting since Inception (March 5, 2013) and of American Cannabis Company, Inc. (formerly BIMI) since September 29, 2014.

Results of Operations 

For the three months ended September 30, 2017 compared to three months ended September 30, 2016.

The following table presents our consolidated operating results for the three months ended September 30, 2017 compared to the three months ended September 30, 2016:

  Three Months   Three Months    
  Ended   Ended    
  September 30, % of September 30, % of  
  2017 Revenues 2016 Revenues $ Change
Revenues                    
Consulting services $916,676   92.6   143,610   60.6  $704,813 
Products and equipment  73,637   7.4   93,290   39.4   (158,148)
Total revenues  990,313   100.0   236,900   100.0   521,568 
Costs of revenues                   ��
Cost of consulting services  124,367   12.6   38,120   16.1   73,089 
Cost of products and equipment  38,824   3.9   66,614   28.1   (107,024)
Total costs of revenues  163,501   16.5   104,734   44.2   (33,625)
Gross profit  826,812   83.5   132,166   55.8   580,290 
Operating expenses                    
General and administrative  362,966   36.7   353,290   149.1   9,676 
Investor relations  10,381   1.0   11,129   4.6   9,488 
Selling and marketing  72,115   7.3   22,855   9.6   52,453 
Research and development  6,368   0.6   520   0   4,955 
Total operating expenses  451,830   45.6   387,796   163.3   64,034 
Income (loss) from operations  374,982   37.9   (255,630)  (107.9)  630,612 
Other income (expense)                    
Interest expense, net  156   0.0   (19,605)  8.3   156 
Total other income (expense)  156   0.0   (14,314)  (6.0)  1532 
Net income (loss) before income taxes $375,138   37.9  $(269,944)  (113.9) $645,082 
Income tax expense (benefit)  0   0   0   0.0   0 
Net income (loss) $375,138   37.9  $(269,944)  (113.9) $645,082 

13

Revenues 

Total revenues were $990,313 for the three months ended September 30, 2017 as compared to $236,900 for the three months ended September 30, 2016, an increase of $753,413. This increase was due to increased consulting and product sales in new markets. Consulting service revenues increased for the three months ended September 30, 2017, to $916,676 or 92.6% of total revenues, versus $143,610 or 60.6% of total revenues for the three months ended September 30, 2016. We experienced a decrease in our product and equipment revenues as amounts for the three months ended September 30, 2017 were $73,637 or 7.4% of total revenues, versus $93,290 or 39.4% of total revenues for three months ended September 30, 2016. This decrease was due to the cyclical nature of the Company’s business as product and equipment sales follow on successful consulting services.

Costs of Revenues 

Costs of revenues primarily consist of labor, travel, and other costs directly attributable to providing services or products. During the three months ended September 30, 2017, our total costs of revenues were $163,501, or 16.5% of total revenues. This compares to total costs of revenues for the three months ended September 30, 2016 of $104,734 or 44.2% of total revenues. The increase in costs of revenues of $22,767 was primarily due to increased costs of consulting services. For the three months ended September 30, 2017, consulting-related costs were $124,367, or 12.6% of total revenue, as compared to costs of $38,120, or 16.1% of revenue for the three months ended September 30, 2016. Costs associated with products and equipment were $38,824, or 3.9% of total revenue for the three months ended September 30, 2017 as compared to $66,614, or 28.1% of total revenue for the three months ended September 30, 2016. As a percentage of revenues, the decrease was attributed to the lifecycle of client contracts with the company experiencing spikes in product revenues during design and facility build-outs. The company was not performing any design and facility build-outs for the three months ended September 30, 2017, while two facility build-outs were in-progress during the three months ended September 30, 2016.

Gross Profit

Total gross profit was $826,812 for the three months ended September 30, 2017, comprised of consulting services gross profit of $791,999 and products and equipment gross profit of $34,813. This compares to total gross profit of $132,166 for the three months ended September 30, 2016, comprised of consulting services gross profit of $105,490 and products and equipment gross profit of $26,676. The increase of $686,509 for consulting services gross profit was due to growth in our new consulting client base and volume of operations. As a percentage of total revenues, gross profit was 83.5% for the three months ended September 30, 2017 as compared to 55.8% for the three months ended September 30, 2016.

Operating Expenses

Total operating expenses were $451,830, or 45.6% of total revenues for the three months ended September 30, 2017, compared to $387,796, or 163.7% of total revenues for the three months ended September 30, 2016. This decrease was primarily due to efficiencies in operations.

Other Income (Expense) 

Other income (expense) for the three months ended September 30, 2017 was an expense of $156 as compared with an expense of $(14,314) for the three months ended September 30, 2016.

Net Income (Profit)

As a result of the factors discussed above, net income (expense) for the three months ended September 30, 2017 was a net profit of $375,138, or 37.9% of total revenues for the period, as compared to a net loss of ($269,944), or (113.9%) of total revenues for the three months ended September 30, 2016, due to the Company being well positioned to capitalize on the growing industry following the November 2016 election.

14


Liquidity and Capital Resources

As of September 30, 2017, our primary internal sources of liquidity were our working capital, which included cash and cash equivalents of $1,877,249 and accounts receivable of $404,894. We also have the ability to raise additional capital as needed through external equity financing transactions. Additionally, considering that our fixed overhead costs are low, we have the ability to issue stock to compensate employees and management, and the level of future revenue we expect to generate from executed client contracts, we believe our liquidity and capital resources to be adequate to fund our operational and general and administrative expenses for at least the next 12 months without needing to raise additional debt or equity funding. There is no guarantee we will have the ability to raise additional capital as needed through external equity financing transactions if required.

Operating Activities

Net cash used in by operating activities for the three months ended September 30, 2017 was a use of $528,518 consisting of net gain of $498,964, decreases in accounts payable of $44,640 due to inventory product purchases, and decrease in advances from clients $164,388 which related to recognition of revenues from advances received during 2017 and inventory of $30,640 based on product purchases. Net cash used in operating activities for the three months ended September 30, 2016 was a use of $619,983, consisting of net loss of ($368,276), decreases in accounts payable of $117,206 due to inventory product purchases, an increase in advances from clients $57,326 which related to recognition of revenues from advances received during 2016 and inventory of $42,500 based on product purchases. 

Investing Activities

For the months ended September 30, 2017 and 2016, investing activities were a use of cash of ($5,000) and 0 respectively.

Financing Activities

For the months ended September 30, 2017 and 2016, the net cash from financing activities was $0 and $139,065 respectively.  

Off Balance Sheet Arrangements

As of September 30, 2017, and December 31, 2016, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Non-GAAP Financial Measures

We use Adjusted EBITA, a non-GAAP metric, to monitor our overall business performance. We define Adjusted EBITA as net income (loss) before interest expense, net, provision for (benefit from) income taxes, stock-based compensation and certain non-recurring expenses. We believe that such adjustments to arrive at Adjusted EBITA provides us with a more comparable measure for managing our business. We also believe that it is a useful measure for securities analysts, investors, and other interested parties in the evaluation of our Company.

A reconciliation of net income (loss) to Adjusted EBITA is provided below.

  Three Months Ended Three Months Ended
  September 30, 2017 September 30, 2016
  (Unaudited) (Unaudited)
Adjusted EBITA reconciliation:        
Net income (loss)  375,138   (269,944)
Stock-based compensation expense  0   12,991 
Interest expense, net  156   19,605 
Tax expense (benefit)  0   0 
Adjusted EBITA $375,294  $(250,339)

2515
 

ITEM 3. QUANTITATIVE & QUALITATIVE DISCLOSURES ABOUT MARKET RISK

AMERICAN CANNABIS COMPANY, INC.

We are a smaller reporting Company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE SIX AND THREE MONTHS ENDED JUNE 30, 2023 AND 2022

Note 14. Stock-Based Compensation

During the six months ending June 30, 2023, the Company issued no stock-based compensation for employees and service providers per its 2015 Equity Incentive Plan.

26

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE SIX AND THREE MONTHS ENDED JUNE 30, 2023 AND 2022

Note 15. Shareholders’ Equity

Preferred Stock

American Cannabis Company, Inc. is authorized to issue 5,000,000 shares of preferred stock at $ 0.00001 par value. No shares of preferred stock were issued and outstanding at June 30, 2023, and December 31, 2022, respectively.

Common Stock

American Cannabis Company, Inc. is authorized to issue 500,000,000 shares of common stock at 0.00001 par value. At June 30, 2023, 92,152,938 shares were outstanding.

During the three and six months ended June 30, 2023, the Company issued no shares of common stock.

During the six months ended June 30, 2022, the Company issued 2,175,000 restricted shares valued at $43,500 granted during the fiscal year ending December 31, 2022.

Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the reporting period. Diluted net loss per share is computed similarly to basic loss per share, except that it includes the potential dilution that could occur if dilutive securities are exercised.

Outstanding stock options and common stock warrants are considered anti-dilutive because we are in a net loss position.  Accordingly, the number of weighted average shares outstanding for basic and fully diluted net loss per share are the same. At June 30, 2023, the Company did not have any warrants or options issued and outstanding.

Note 16. Commitments and Contingencies

Legal

In the ordinary course of its business, the Company becomes involved in various legal proceedings involving a variety of matters. The Company does not believe there are any pending legal proceedings that will have a material adverse effect on the Company’s business, consolidated financial position, results of operations, or cash flows. However, the outcome of such legal matters is inherently unpredictable and subject to significant uncertainties. The Companies expenses legal fees in the period in which they are incurred.

27

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE SIX AND THREE MONTHS ENDED JUNE 30, 2023 AND 2022

Note 17. Subsequent Events

In accordance with ASC 855-10, the Company has analyzed its operations after unaudited consolidated financial statements were available to be issued and determined that there were no other significant subsequent events or transactions that would require recognition or disclosure in the unaudited condensed consolidated financial statements for the six months ended June 30, 2023, and did not find any events.

28

ITEM 4.2.CONTROLSMANAGEMENT’S DISCUSSION AND PROCEDURESANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ManagementThe statements contained in this report that are not statements of historical fact, including, without limitation, statements containing the words “believes,” “expects,” “anticipates,” and similar words constitute forward-looking statements that are subject to a number of risks and uncertainties. From time to time, we may make other forward-looking statements. Investors are cautioned that such forward-looking statements are subject to an inherent risk that actual results may materially differ as a result of many factors, including the risks discussed from time to time in this report, including the risks described under “Risk Factors” in any filings we have made with the SEC.

Government Regulation

Currently, thirty-six states plus the District of Columbia have laws and/or regulations that recognize, in one form or another, legitimate medical uses for cannabis and consumer use of cannabis in connection with medical treatment. Currently, sixteen states and the District of Columbia allow recreational use of cannabis. As of June 30, 2023, the policy and regulations of the CompanyFederal Government and its agencies are that cannabis has no medical benefit and a range of activities, including cultivation and use of cannabis for personal use, is responsible for maintaining disclosure controlsprohibited based on federal law and procedures that are designed to ensure that financial information required tomay or may not be disclosed in the reports that the Company files or submits under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported within the timeframes specified in the Securities and Exchange Commission’s rules and forms, consistent with Items 307 and 308 of Regulation S-K.

In addition, the disclosure controls and procedures must ensure that such financial information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial and other required disclosures.

As of September 30, 2017, an evaluationpermitted based on state law. Active enforcement of the effectivenesscurrent federal regulatory position on cannabis on a regional or national basis may directly and adversely affect the willingness of customers of the Company’s disclosure controls and procedures (as definedmedicinal cannabis products to invest in Rules 13(a)-15(e) and 15(d)-15(e)or buy products. Active enforcement of the Securities Exchange Actcurrent federal regulatory position on cannabis may thus indirectly and adversely affect the revenues and profits of 1934 (the “Exchange Act”) was carried outthe Company.

Our discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses. On an ongoing basis, we evaluate these estimates, including those related to the useful lives of real estate assets, bad debts, impairment, net lease intangibles, contingencies, and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the supervisioncircumstances, the results of which form the basis for making judgments about the carrying values of assets and withliabilities that are not readily apparent from other sources. There can be no assurance that actual results will not differ from those estimates.

BACKGROUND

American Cannabis Company, Inc. and subsidiary company, Hollister & Blacksmith, Inc., doing business as American Cannabis Consulting (“American Cannabis Consulting”), (collectively “the “Company”, “we”, “us”, or “our”) are based in Denver, Colorado and operate a fully integrated business model that features end to end solutions for businesses operating in the participation of our Chief Executive Officer, Chief Financial Officer,regulated cannabis industry in states and other persons carrying out similar functionscountries where cannabis is regulated and/or has been decriminalized for medical use and/or legalized for recreational use. The Company provides advisory and consulting services specific to this industry and manufactures proprietary industry solutions, including; the Company. BasedSatchel™, SoHum Living Soils™, Cultivation Cube™, and the High-Density Cultivation System.™ The Company also sells third-party industry-specific products and manages a strategic group partnership that offers both exclusive and nonexclusive customer products commonly used in the industry. American Cannabis Company, Inc. is a publicly listed third-party industry-specific quoted on the evaluationOTCQB Tier under the symbol “AMMJ”.

Naturaleaf Acquisition

On April 30, 2021, the Company closed its acquisition of the Company’s disclosure controlsassets of Medihemp, LLC, and procedures,its wholly owned subsidiary SLAM Enterprises, LLC, and Medical Cannabis Caregivers, Inc., each an entity organized and operating under the laws of the State of Colorado, and all doing business as “Naturaleaf” in the medicinal cannabis industry in Colorado.

29

Medihemp and SLAM, respectively own fixed assets and operate two retail Medical Marijuana Centers located in Colorado Springs, Colorado. Medical Cannabis owns fixed assets and operates a retail Medical Marijuana Center located in Colorado Springs, Colorado. Medical Cannabis also owns and operates a Medical Marijuana Optional Premises Cultivation license, and a Medical Marijuana-Infused Product Manufacturer license.

30

Naturaleaf agreed to sell or assign to the Company concluded that during the period covered by this report, such disclosure controls and procedures were not effective.following assets:

1.Three Medical Marijuana (MMC) Store Licenses;

2.One Marijuana Infused Product Licenses (MIPS); and,

3.One Option Premises Cultivation License (OPC); and,

4.Related real property assets, goodwill, and related business assets.

The Company continues to employ and refineAs a structure in which critical accounting policies, issues and estimates are identified, and together with other complex areas, are subject to multiple reviews by accounting personnel. In addition,result, the Company evaluateshas expanded its business model to include the cultivation and assessesretail sale of cannabis in the medicinal cannabis industry.

On May 31, 2023, the Company sold Colorado State License No. 402-01065 (Medical Marijuana Store); City of Colorado Springs License No. 0850714L in exchange for $100,000. As of May 31, 2023, the Company discontinued its internal controls and procedures regarding its financial reporting, utilizing standards incorporating applicable portions ofoperations at the Public Company Accounting Oversight Board’s 2009 Guidance for Smaller Public Companies in Auditing Internal Controls Over Financial Reporting as necessary and on an on-going basis.

Because of its inherent limitations, internal control over financial reporting cannot provide absolute assurance of the prevention or detection of misstatements. In addition, projections of any evaluation of effectiveness to future periods are subject to risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Changes in Internal Control over Financial Reporting

The Company had no reportable changes to its internal controls over financial reporting for the period covered by this report.

Palmer Park Boulevard, Ste. A, Colorado Springs, CO location. The Company will continually enhance and test its internal controls over financial reportingcontinue to rent the facility on a continuing basis. Additionally,month-to-month tenancy pending final regulatory approval from the Company’s management, underColorado Marijuana Enforcement Division concerning the controlchange of its Chief Executive Officer and Chief Financial Officer, will increase its review of its disclosure controls and procedures on an ongoing basis. Finally,ownership.

RESULTS OF OPERATIONS

AMERICAN CANNABIS COMPANY, INC. 

CONSOLIDATED STATEMENTS OF OPERATIONS

For the Company plans to designate, in conjunction with its Chief Financial Officer, individuals responsible for identifying reportable developments and the process for resolving compliance issues related to them. The Company believes these actions will focus necessary attention and resources in its internal accounting functions.

Six Months Ended  

 

       
  June 30, June 30, Increase
  2023 2022 (Decrease)
Revenues            
Consulting Services $468,500  $242,048   226,452 
Product & Equipment  737,758   4,673,833   (3,936,076)
Cannabis Products  347,819   448,249   (100,430)
Total Revenues  1,554,077   5,364,131   (3,810,454)
Cost of Revenues            
Cost of Consulting Services  103,085   47,922   55,163 
Cost of Products and Equipment  507,646   3,964,197   (3,456,551)
Cost of Cannabis Products  357,771   543,828   (186,057)
Total Cost of Revenues  968,502   4,555,947   (3,587,445)
Gross Profit  585,575   808,184   (222,609)
           —   
Operating Expenses  —           
General and Administrative  1,081,600   1,333,738   (252,138)
Selling and Marketing  117,384   101,527   15,857 
Stock Based Compensation Expense  17,021   65,309   (48,288)
Total Operating Expenses  1,216,005   1,500,574   (284,569)
Loss from Operations  (692,390)  (584,081)  (108,309)
Other Income (Expense)            
Interest (expense)  (64,363)  (18,810)  (26,546)
Debt Forgiveness  —     110,543   (110,543)
Other income  181,316   1,799   42,970 
Total Other (Expense) Income  116,953   93,532   (94,120)
Net Loss  (692,978)  (490,549)  (202,429)
Income Tax Expense  —     —     —   
NET LOSS $(692,978) $(490,549)  (202,429)

31
 

Revenues

Total revenues were $1,554,077 for the six months ending June 30, 2023, compared to $5,364,131 for the six months ending June 30, 2022. The decrease in total revenue of $3,180,054 represents decreases in the revenue streams from the sale of equipment and cannabis products of $3,936,079 and $100,430, respectively.

Total revenues were $841,692 for the three months ending June 30, 2023, compared to $4,744,285 for the three months ending June 30, 2022. The decrease in total revenue of $3,986,480 for the three months ended June 30, 2022, represents a decrease in equipment sales.

Costs of Revenues

Costs of revenues primarily consist of labor, travel, cost of equipment, and other costs directly attributable to providing equipment, soil, and cannabis products. Costs of revenues related to our cannabis products include cultivation costs, including labor, utilities, supplies, and cultivation facility rent. During the six months ended June 30, 2023, our total costs of revenues were $968,502 compared to $4,555,947 for the six months ended June 30, 2022. The decrease of $3,587,445 in cost of revenues was a direct result of decreases in costs associated with equipment sales.

During the three months ended June 30, 2023, our total costs of revenues were $532,626 compared to $4,103,649 for the three months ended June 30, 2022. The decrease of $3,571,023 in cost of revenues was a direct result of decreased costs associated with equipment sales.

Consulting Services

Consulting service revenues during the six months ended June 30, 2023, were $468,500 versus $242,048 for the six months ended June 30, 2022, and $307,685 and $146,976 for the three months ended June 30, 2023, and 2022, respectively. Increases in consulting services result from the number and size of the type of projects worked on in the second quarter compared to the projects in the second quarter of 2022. Projects over the first six months of 2023 focused on assisting with licensing and providing proforma and design services. The first six months of 2023 saw an increase in projects overseeing and managing projects involving the implementation of design work provided for certain clients. As a result, while equipment sales decreased over the prior period, we saw an increase in consulting sales over the prior period.

Costs of Services were $103,085 compared to $47,922 for the six months ended June 30, 2023, and 2022, and $58,085 and $31,515 during the three months ended June 30, 2023, and 2022, respectively. Costs associated with consulting services increased due to the increase in payroll expenses allocated to the cost of services.

Soil Product and Equipment Revenues

Our product and equipment revenues for the six months ended June 30, 2023, were $737,758 versus $4,673,834 for the six months ended June 30, 2022, and $374,209 and $4,360,689 for the three months ended June 30, 2023, and 2022, respectively. Decreases in soil and equipment product sales increased to $3,936,076 from $3,986,480 during the six months ended June 30, 2023, compared to the six months ended June 30, 2022. During the six months ending June 30, 2023, the Company experienced cyclical downturns in the number of consulting projects that focused on constructing or improving cultivation facilities. This has resulted, and the Company anticipates seeing significantly less activity in equipment sales during the period.

Costs of Products and Equipment were $507,646 and $3,964,197 during the six months ended June 30, 2023, and 2022. Decreased costs were the result of lower associated with products and equipment sales.

Cannabis Product Revenues

Cannabis product revenues during the three months ended June 30, 2023 and 2022 were $159,798 and $236,620 respectively. During the six months ended June 30, 2023, and 2022, Cannabis product revenues were $347,819 and $448,249, respectively. The decrease of $76,822 and $100,430 were due to decreased sales during the respective periods.

Costs associated with cannabis products consist of those costs incurred in the cultivation of the plants and the retail sale of the products. During the three months ended June 30, 2023, and 2022, such costs were $184,062 and $354,157. During the six months ended June 30, 2023, and 2022, such costs were $357,771 and $543,828, respectively. The respective decreases in costs of $170,095 and $186,057 reflect decreased investment in infrastructure remodeling and upgrades.

Gross Profit

Total gross profits were $309,066 for the three months ended June 30, 2023, compromised of consulting services gross profit of $249,600, products and equipment gross profit of $84,130, and a gross profit of ($24,064) for cannabis products. This compares to a total gross profit of $640,636 for the three months ended June 30, 2022, comprised of consulting services gross profit of $115,461 and products and equipment gross profit of $43,878, and a gross profit of ($117,537) for cannabis products.

Total gross profits were $585,575 for the six months ended June 30, 2023, comprised of consulting services gross profits of $365,415, products and equipment gross profit of $230,112, and a gross profit of ($9,952). This compares to a total gross profit for the six months ended June 30, 2022, of consulting services gross profits of $194,126, products and equipment gross profit of $709,637, and cannabis products gross profits of ($95,579).

Operating Expenses

Total operating expenses were $1,216,004 for the six months ended June 30, 2023, and $1,500,574 for the six months ended June 30, 2022. The decrease of $284,570 in operating expenses is attributed to lower general and administrative expenses associated with maintaining the operations. The Company has seen additional increases in depreciation and amortization expenses, sales, and marketing expenses during the period. 

1632
 

Other Income (Expense)

Other income (expense) for the six months ending June 30, 2023, was $116,953 compared with $93,532 for the six months ending June 30, 2022.

Net Loss

Net loss for the six months ending June 30, 2023, was ($692,978) compared to a net loss of ($490,549) for the six months ending June 30, 2022.

Net loss for the three months ending June 30, 2023, was ($591,433) compared to a net loss of ($170,803) for the three months ending June 30, 2022.

LIQUIDITY AND CAPITAL RESOURCES

As of June 30, 2023, our primary internal sources of liquidity were our working capital, which included cash and cash equivalents of $81,705 and accounts receivable of $293,304. Additionally, considering that our fixed overhead costs have increased over the last year, management has instigated and continues to investigate opportunities for financing to support operations and growth. Management believes this strategy will adequately provide the necessary liquidity and capital resources to fund our operational and general and administrative expenses for at least the next 12 months.

Operating Activities

Net cash provided by operating activities for the six months ended June 30, 2023, was ($182,399), compared to net cash used by operating activities of $646,707, for the six months ended June 30, 2022. Increases in cash used resulted from decreased accounts receivable by increases in accounts payable. All a direct result of the decreased activities in equipment sales.

During the six months ending June 30, 2023, the Company has entered into consulting projects focused on constructing or improving cultivation facilities. The Company anticipates seeing greater activity in equipment sales and, therefore will see significant changes in Advances from Clients and other associated balance sheet accounts, such as prepaid expenses, accounts receivable, and accounts payable. In the case of equipment sales, the Company purchases the required equipment from 3rd party suppliers. Equipment purchases are not made until the Client has approved the estimates, been invoiced, and paid the invoice. The Company will not recognize these revenues until the equipment has been delivered to and received by the client.

Investing Activities

For the six months ended June 30, 2023, and 2022, investing activities were a use of cash of ($39,101) and ($10,998) respectively. These funds were used to purchase property and equipment, furniture and fixtures, and office equipment for $28,103.

Financing Activities

During the six months ended June 30, 2023, proceeds used in financing activities were $185,660, and ($432,371) for the six months ended June 30, 2022. Funds received during the six months ended June 30, 2023, were proceeds from notes. During the six months ended June 30, 2022, the Company paid down the Naturaleaf note payable. 

33

PART II—OTHER INFORMATIONOff Balance Sheet Arrangements

As of June 30, 2023, and December 31, 2022, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Non-GAAP Financial Measures

Adjusted EBITDA, a Non-GAAP metric, is used to monitor our overall business performance. We define Adjusted EBITDA as net income (loss) before interest expense, net, provision for (benefit from) income taxes, stock-based compensation, and certain nonrecurring expenses, which have been limited to costs associated with the Reverse Merger. We believe such adjustments to arrive at Adjusted EBITDA provide us with a comparable measure for managing our business. We also believe that it is a useful measure for securities analysts, investors, and other interested parties in evaluating our Company.  

A reconciliation of net income(loss) to Adjusted EBITDA is provided below:

  Six Months
 Ended June 30, 2022 Ended June 30, 2023
Adjusted EBITDA reconciliation:        
Net loss  (508,476) $(692,978)
Depreciation and Amortization  121,449   72,520 
Interest Expense  64,363   45,356 
Stock-based compensation for services  —     13,542 
Stock-based compensation to employees  —     65,306 
Adjusted EBITDA  (322,664) $(496,251)

ITEM 3. QUANTITATIVE & QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting Company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer/Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

We carried out an evaluation under the supervision and with the participation of management, including our Chief Executive Officer/Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2023, the end of the period covered by this Report.  Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses discussed below. 

34

Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive officer and principal financial officer and effected by the Board, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures that:

opertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets,
oprovide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and,
oprovide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.

Because of our inherent limitations, our internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any effectiveness evaluation to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

Management identified the following material weaknesses:

·we do not have an Audit Committee – While not being legally obligated to have an Audit Committee, it is the management’s view that such a committee, including a financial expert board member, is an utmost important entity level control of the Company’s financial statements. Currently the Board of Directors acts in the capacity of the Audit Committee and does not include a member that is considered to be independent of management to provide the necessary oversight over management’s activities.

we have not performed a risk assessment and mapped our processes to control objectives.

we have not implemented comprehensive entity-level internal controls.

we have not implemented adequate system and manual controls; and

we do not have sufficient segregation of duties.

Our management assessed the effectiveness of internal control over financial reporting as of June 30, 2023.  In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organization of the Treadway Commission (“COSO”) in Internal Control–Integrated Framework (2013).  Based on management’s assessment, management concluded that the above material weaknesses have not been remediated and, accordingly, our internal control over financial reporting is not effective as of June 30, 2023. 

35

Remediation of Material Weaknesses

We have designed and plan to implement, or in some cases have already implemented, the specific remediation initiatives described below:

● We intend to allocate resources to perform a risk assessment and map processes to control objectives and, where necessary, implement and document internal controls in accordance with COSO.

● Our entity-level controls are generally informal, and we intend to evaluate current processes, supplement where necessary, and document requirements.  

● While we have implemented procedures to identify, evaluate and record significant transactions, we need to formally document these procedures and evidence the performance of the related controls.  

● We plan to evaluate system and manual controls, identify specific weaknesses, and implement a comprehensive system of internal controls.

PART II—OTHER INFORMATION

ITEM 1.LEGAL PROCEEDINGS

On July 31, 2017, the Company entered into a settlement agreement, mutual release of all claims and waiver of bond for lost certificate, with Private Media Group, Inc. On May 23, 2014, Private Media Group, Inc. was issued 200,000 shares of common stock as consideration for services rendered. Private Media Group, Inc. subsequently lost the stock certificate, and demanded the Company reissue the common stock. The Company and Private Media Group, Inc. entered into a settlement agreement provided that in exchange for a complete release of all claims regarding any and all compensation due to Private Media Group, Inc., Private Media Group, Inc. agreed to return 100,000 shares to treasury, and the Company agreed to waive of bond for the lost certificate, and to reissue Private Media Group, Inc. 100,000 common shares of common stock.

On August 31, 2017, the Company entered into a settlement agreement and mutual release of all claims with Anthony Baroud. The Company previously disclosed its participation in a private arbitration proceeding conducted by the American Arbitration Association, in which both claims and counterclaims were asserted by the respective parties. The settlement agreement disposed of the arbitration proceeding and all claims and counterclaims between the parties with prejudice. As consideration for the dismissal and mutual release of all claims, the Company agreed to a stock compensation settlement equal to $110,000 consisting of an issuance of 100,000 shares of common stock to Mr. Baroud, valued for the purposes of the settlement agreement at $0.93 per share, for a total of $93,000, and fully vested warrants to purchase up to fifty thousand (50,000) shares of common stock in a cashless transaction at an exercise price determined by the closing price of the Company’s common stock on March 1, 2018. The warrants expire on March 1, 2018. If the 50,000 shares issuable to Mr. Baroud pursuant to the Cashless Warrant Agreement does not equal $17,000 for a total of $110,000, the Company agreed to issue Mr. Baroud restricted common stock, valued as of the closing price on March 1, 2018, to correct the difference so that Baroud receives the equivalent of $110,000.00.

ITEM 1A.RISK FACTORS

We are a smaller reporting Company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

No transactions meetingDuring the reporting requirementssix months ended June 30, 2022, the Company issued 325,000 shares of this item occurredits restricted common stock to officers and directors as stock compensation earned during the periods covered by this report.year ended December 31, 2021.

During the six months ended June 30, 2022, the Company issued 1,000,000 shares of its restricted common stock to a third-party consultant for services.

ITEM 3.DEFAULTS UPON SENIOR SECURITIES

No senior securities were issued and outstanding during the three and nine months ended September 30, 2017 or 2016.March 31, 2022, and 2021.

36

ITEM 4.MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5.OTHER INFORMATION

None.

37
 17

ITEM 6.EXHIBITS

This list is intended to constitute the exhibit index.

31.110.1Amended and Restated Investment Agreement dated August 4, 2016 between the Company and Tangiers Global, LLC.

10.2Amended and Restated Registration Rights Agreement dated August 4, 2016 between the Company and Tangiers Global, LLC.

31.1Certification of Principal Executive Officer as required by Rule 13a-14 or 15d-14 of the Exchange Act, as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2Certification of Principal& Financial Officer as required by Rule 13a-14 or 15d-14 of the Exchange Act, as adopted Pursuantpursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.132.1Certification of Principal Executive Officer Pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2Certification of Principal& Financial Officer Pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-OxleySarbanes0Oxley Act of 2002.

101.INS101.INSXBRL Instance Document*

101.SCH101.SCHXBRL Taxonomy Extension Schema Document*

101.CAL101.CALXBRL Taxonomy Extension Calculation Linkbase Document*

101.DEF101.DEFXBRL Taxonomy Extension Definition Linkbase Document*

101.LAB101.LABXBRL Taxonomy Extension Label Linkbase Document*

101.PRE101.PREXBRL Taxonomy Extension Presentation Linkbase Document*

*Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities and Exchange Act of 1934, and otherwise are not subject to liability under those sections.

3818
 

SIGNATURES

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

American Cannabis Company, Inc.AMERICAN CANNABIS COMPANY, INC.

Date: November 20, 2017August 14, 2022

By:/s/

By:  /s/ Ellis Smith

Terry Buffalo, Ellis Smith, 

Chief Executive Officer

(Principal Executive Officer)

Date: November 20, 2017

By:/s/

J. Michael Tuohey, & Chief Financial Officer

(Principal Financial Officer)

1939